The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.

Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. The mechanism of action of TGV has not been clearly defined despite the identification of resistance mutations mapping to the NS5B...

Descripción completa

Detalles Bibliográficos

Autores principales:	Christy M Hebner, Bin Han, Katherine M Brendza, Michelle Nash, Maisoun Sulfab, Yang Tian, Magdeleine Hung, Wanchi Fung, Randall W Vivian, James Trenkle, James Taylor, Kyla Bjornson, Steven Bondy, Xiaohong Liu, John Link, Johan Neyts, Roman Sakowicz, Weidong Zhong, Hengli Tang, Uli Schmitz
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Public Library of Science (PLoS) 2012-01-01
Colección:	PLoS ONE
Acceso en línea:	https://doi.org/10.1371/journal.pone.0039163
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!